Tagged Articles

Natrecor 2 articles

Drug companies’ high-dollar settlements for false claims could be coming to end

Johnson & Johnson’s $2.2 billion settlement to resolve False Claims Act allegations that it paid doctors kickbacks and promoted some drugs for off-label uses may be one of the last high-dollar settlements in the federal government’s long-running campaign to stop drug companies from marketing drugs for uses in which they are not approved. Johnson & Johnson was ordered to pay the 10-figure settlement based on illegal marketing of three of its drugs including the antipsychotic Risperdal, the schizophrenia drug Invega, and the cardiac drug Natrecor. The practice, attorneys said, put fragile patients – such as the elderly and children – ... Read More

Johnson & Johnson agrees to a settlement of $2.2 billion to end U.S. investigations

Pharmaceutical giant Johnson & Johnson, and its subsidiaries, has agreed to pay $2.2 billion in an effort to end civil and criminal investigations into kickbacks the company allegedly paid to pharmacists and physicians to promote three prescription drugs for off-label uses unapproved by the U.S. Food and Drug Administration (FDA), according to the Department of Justice. The settlement involved the marketing of Risperdal and Invega, both drugs originally designated for schizophrenia and bipolar disorder treatment, and the heart failure drug, Natrecor. This is one of the largest health care fraud settlements in U.S. history. Risperdal, sold by J&J firm Janssen Pharmaceuticals, ... Read More